FFFrancesca Franchina

Francesca Franchina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesca Franchina has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plant-Based Diets and Thyroid Homeostasis in Children and Adolescents: Balancing Anti-Inflammatory Potential and Micronutrient Vulnerability

    by Giovanni Luppino, Francesca Franchina, Matteo Pontone, Malgorzata Wasniewska, Stefano Stagi

    Plant-based diets are increasingly common among children and adolescents because of their potential health benefits, environmental sustainability, and ethical considerations. However, their implications for thyroid health during growth and development remain incompletely characterised. The effects of plant-based diets on thyroid function may depend on overall diet quality and the extent of exclusion of animal-derived foods. Well-planned plant-based diets provide bioactive compounds, dietary fibre, and unsaturated fatty acids that may reduce oxidative stress and inflammation, promote a healthy gut microbiota, and support immune homeostasis. Conversely, poorly planned diets, particularly those rich in ultra-processed foods, may promote inflammation, oxidative stress, and intestinal dysbiosis. Vegetarian and vegan diet patterns may also increase the risk of inadequate intake of iodine, iron, zinc, selenium, and vitamins, while some plant-derived foods, including soy products and cruciferous vegetables, may influence thyroid physiology. These issues are particularly relevant during childhood, when thyroid hormones are essential for neurodevelopment, growth, and metabolic regulation. Current evidence suggests that thyroid health depends primarily on overall diet quality and micronutrient adequacy rather than the exclusion of animal-derived foods itself. This review critically examines these relationships, with particular emphasis on paediatric evidence.

  • Open Access

    The Influence of Ultra-Processed Foods on Inflammation and Metabolic Health in Pediatric Obesity: A Systematic Review with a Narrative Synthesis

    by Debora Porri, Malgorzata Wasniewska, Alessandra Li Pomi, Elisa La Rosa, Giovanni Luppino, Aurora Lanzafame, Cecilia Lugarà, Roberto Coco, Francesca Franchina, Tiziana Abbate, et al.

    The increasing prevalence of childhood obesity has been accompanied by an increase in consumption of ultra-processed foods (UPF), characterized by high energy density and low nutritional quality. Emerging evidence suggests that dietary patterns rich in UPF may contribute to low-grade systemic inflammation and early metabolic dysfunction in children and adolescents. Objective: This systematic review aimed to evaluate the association between UPF consumption and markers of inflammation and metabolic health in pediatric populations. Methods: A systematic literature search was conducted on PubMed in accordance with PRISMA guidelines. Observational and interventional studies evaluating UPF intake or diet-related inflammatory potential in children and adolescents (≤18 years) were included. Outcomes of interest included inflammatory biomarkers (e.g., C-reactive protein, interleukins, tumor necrosis factor-α) and metabolic parameters (e.g., insulin resistance, lipid profile, glucose metabolism). Results: A limited number of studies have directly assessed UPF consumption using the NOVA classification. Overall, these studies suggest a potential association between increased UPF intake and adverse metabolic outcomes, although findings on inflammatory markers remain inconsistent. A larger body of indirect evidence, including studies assessing dietary inflammatory indices and related dietary patterns, consistently supports a link between pro-inflammatory diets and increased inflammation and metabolic dysregulation in pediatric populations. Conclusions: Although direct evidence on UPF consumption remains limited, the available findings, supported by complementary indirect evidence, suggest a plausible relationship between UPF-rich diets, inflammation, and metabolic health in children and adolescents. Further well-designed studies are needed to clarify causality and improve the standardization of dietary assessment methods.


  • Open Access

    Exploring Autosomal Dominant Non-Syndromic Monogenic Obesity: From Genes to Therapy

    by Giovanni Luppino, Mara Giordano, Francesca Franchina, Roberto Coco, Eleonora Inì, Carla Fazio, Debora Porri, Cecilia Lugarà, Domenico Corica, Tommaso Aversa, et al.

    Genetic factors are key determinants in the pathophysiology of obesity, regulating energy homeostasis. Monogenic non-syndromic obesity accounts for 2–3% of obesity in both children and adults and is most often attributable to mutations in genes encoding components of the leptin–melanocortin pathway. Genetic testing is indicated in children with severe obesity before age 5, hyperphagia, a family history of obesity, and neurodevelopmental delay or organ dysfunction. Mutations associated with monogenic obesity follow autosomal recessive (LEP, LEPR, POMC, and PCSK1) or autosomal dominant (MC4R, SH2B1, SIM1, GNAS) modes of inheritance. Other gene mutations in heterozygous states (MRAP2, MC3R, SRC1, KSR2) are associated with obesity and may exhibit autosomal dominant inheritance; however, the clinical phenotype depends on the degree of genetic penetrance and interactions with other genetic and/or environmental factors. No approved targeted pharmacotherapies are currently available for autosomal dominant monogenic obesity, and the frequent detection of variants of uncertain significance often hinders timely diagnostic confirmation. The review provides a comprehensive appraisal of autosomal dominant forms of monogenic non-syndromic obesity, analyzing genetic and molecular features, clinical presentations, and therapeutic strategies.


  • Open Access

    Two Years of Growth Hormone Therapy in a Child with Severe Short Stature Due to Overlap Syndrome with a Novel SETD5 Gene Mutation: Case Report and Review of the Literature

    by Giovanni Luppino, Malgorzata Wasniewska, Giorgia Pepe, Letteria Anna Morabito, Silvana Briuglia, Antonino Moschella, Francesca Franchina, Cecilia Lugarà, Tommaso Aversa, Domenico Corica

    Background: SET domain-containing 5 (SETD5) is a member of the protein lysine-methyltransferase family. SETD5 gene mutations cause disorders of the epigenetic machinery which determinate phenotypic overlap characterized by several abnormalities. SEDT5 gene variants have been described in patients with KBG and Cornelia de Lange (CdL) syndromes. Case description: A female patient with severe short stature and intellectual disability had been followed since she was 9 years old. Several causes of short stature were ruled out. At the age of 12 years, her height was 114 cm (−5.22 SDS), weight 19 kg (−5.88 SDS), BMI 14.6 kg/m2 (−2.26 SDS), and was Tanner stage 1. The target height for the proband was 151.65 cm (−1.80 SDS). The bone age (BA) was delayed by 3 years compared to chronological age. The growth rate was persistently deficient (<SETD5 gene mutation (c.890_891delTT), responsible for phenotypes in the context of an overlap syndrome between the phenotype of MDR23, CdL and KBG syndromes. Recombinant growth hormone therapy (rhGH) was started at the age of 12 years. After both one year (+3.16 SDS) and two years (+2.9 SDS), the growth rate significantly increased compared with the pre-therapy period. Conclusion: This is the first case of a patient with overlap syndrome due to SETD5 mutation treated with rhGH. The review of the scientific literature highlighted the clinical and molecular features of SETD5 gene mutation and the use of rhGH therapy in patients suffering from CdL and KBG syndromes.